Human physiology is the science of the mechanical, physical, and biochemical functions of humans in good health, their organs, and the cells of which they are composed. The principal level of focus of physiology is at the level of organs and systems. Most aspects of human physiology are closely homologous to corresponding aspects of animal physiology, and animal experimentation has provided much of the foundation of physiological knowledge. Anatomy and physiology are closely related fields of study: anatomy, the study of form, and physiology, the study of function, are intrinsically tied and are studied in tandem as part of a medical curriculum.
Curemark, LLC, a drug research and development company focused on the treatment of neurological diseases, announced that it has added two sites in California to its Phase III clinical trial program for CM-AT, the company's autism treatment.
Ask someone in the know to list the substances in breast milk that make it the ideal food for newborns and you may hear about proteins that guard against infection, fats that aid in the development of the nervous system and carbohydrates that promote the growth of healthy bacteria. But, you may not hear too much about the nitrite and nitrate in breast milk and their contributions to developing gastrointestinal, immune and cardiovascular systems.
Archimedes Inc., a healthcare modeling company, announced today the launch of the Archimedes Outcomes Analyzer (AOA), a web application that expands access to data sets generated by the Archimedes Model, a large-scale simulation model that calculates clinical and cost outcomes, and answers complex healthcare questions.
Turning up the heat might be the best thing for athletes competing in cool weather, according to a new study by human physiology researchers at the University of Oregon.
Tengion, Inc. a leader in regenerative medicine, presented new data on Saturday, October 23, 2010 in a podium presentation at the American Society for Transplantation's Annual Scientific Exchange in Orlando, FL. The presentation highlighted new early data from Tengion's Neo-Kidney Augment development program demonstrating promising improvements in kidney function with an autologous cellular therapy approach to kidney regeneration in a canine model of chronic kidney disease.
Klaus Ley, M.D, a scientist at the La Jolla Institute for Allergy & Immunology, was recently awarded the prestigious Malpighi Medal at the World Congress for Microcirculation in Paris, France. A lifetime achievement award presented by the European Society for Microcirculation, Dr. Ley received the honor in recognition of his pioneering endeavors in vascular immunology, a scientific discipline that he helped to pioneer, which looks at novel immune-based approaches to combating heart disease. He is only the 17th recipient of the biennial award worldwide.
Taste receptors in the lungs. Researchers at the University of Maryland School of Medicine in Baltimore have discovered that bitter taste receptors are not just located in the mouth but also in human lungs. What they learned about the role of the receptors could revolutionize the treatment of asthma and other obstructive lung diseases.
Researchers at the Swedish medical university Karolinska Institutet have been able to describe the 3D structure of a complete egg receptor that binds sperm at the beginning of fertilization. The results, published in the journal Cell, will lead to better understanding of infertility and may enable entirely new types of contraceptives.
PolyMedix, Inc., a biotechnology company focused on developing new therapeutic drugs to treat infectious diseases and acute cardiovascular disorders, has announced plans for a Phase 2 clinical trial of PMX-60056 in interventional cardiology, and the establishment of a focused Heptagonist Clinical Advisory Board (CAB). PMX-60056 is a synthetic small-molecule designed to reverse the anticoagulant activity of heparin and low molecular weight heparins (LMWH).
A University of Washington Medical Center patient on Thursday, Oct. 21, will be the world's first recipient of a device that aims to quell the disabling vertigo associated with Meniere's disease.
Marc K. Hellerstein, M.D., Ph.D. Co-Founder and Chief of SAB, Kinemed, Inc. presented an "Updated Strategy for Using Disease Predictive Translational Biomarkers in the Rapidly Advancing Field of Causal Pathway Measurements" at the 2010 Personalized and Translational Medicine Conference. In Boston, on September 20-21, 2010.
In a new study it was seen that men diagnosed with coronary heart disease with low testosterone were almost twice as likely to die over a seven year period. The team led by Prof Kevin Channer a cardiologist of the Royal Hallamshire Hospital in Sheffield looked at 930 men for the study. This study is in contrast to the popular belief that testosterone increases heart disease risk. The study was published in the journal Online First Heart.
NanoLogix, an innovator in the accelerated detection and identification of microorganisms, announced today that the University of Texas Health Science Center in Houston is enrolling 300 patients in an ongoing clinical trial to study the speed and accuracy of NanoLogix technology. The trial is designed to compare NanoLogix technology to current methods in use for detection and identification of Group B Streptococcus (GBS) in pregnant women.
The U.S. Department of Defense has awarded researchers at the University of Cincinnati (UC) a $2.1 million Advanced Technology/Therapeutic Development Award to develop the next generation of brain monitors.
Salix Pharmaceuticals, Ltd. today announced the presentation of two analyses of data from its Phase 3 pivotal clinical trials, TARGET 1 and 2, demonstrating a 14-day course of XIFAXAN 550 mg (rifaximin) taken three times daily achieved adequate relief of symptoms of non-constipation irritable bowel syndrome (non-C IBS) in a significantly greater proportion of patients compared with placebo.
UCSF Nobel laureate Stanley B. Prusiner, MD, UCSF professor of neurology and director of the Institute for Neurodegenerative Diseases, today (Oct. 15, 2010) was named to receive the National Medal of Science, the nation's highest honor for science and technology.
Conquering the last frontier for monitoring vital signs, Brain Tunnelgenix Technologies Corp. is introducing the Abreu btt™ 700 System for continuous temperature monitoring at the Annual Meeting of the American Society of Anesthesiologists (ASA) today. The Abreu btt 700 System sensor is approved by the U.S. Food and Drug Administration for placement on the skin and to be used during surgical procedures, recovery room, intensive care and general patient monitoring.
While the blood-brain barrier (BBB) protects the brain from harmful chemicals occurring naturally in the blood, it also obstructs the transport of drugs to the brain. In an article in Nature scientists at the Swedish medical university Karolinska Institutet now present a potential solution to the problem. The key to the BBB is a cell-type in the blood vessel walls called pericytes, and the researchers hope that their findings will one day contribute to new therapies for diseases like Alzheimer's and stroke.
Trials are being organized for a new therapeutic approach to treating cancer, under exclusive license by Viral Genetics, Inc. According to Scott & White Healthcare Senior Vice President for Research Richard E. Beswick, M.D., who is also assistant dean of research at the Texas A&M Health Science Center College of Medicine, the trials will be conducted at the Glenda Tanner Vasicek Cancer Treatment Center, located at Scott & White in Temple, Texas.
According to Dr Peter Biro and his colleagues in their latest study, people obsessed with staying fit may have higher sex drives and also tend to be more aggressive and socially dominant. The team was studying the relationship between behavior and metabolic rate in a number of insects, birds and animals.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.